Influences of dopaminergic treatment on motor cortex in Parkinson disease: A MRI/MRS study

Movement Disorders

Volumn 22, Issue 15, 2007, Pages 2170-2175

  Lucetti, Claudio ^a   Del Dotto, Paulo ^b   Gambaccini, Gianna ^a   Ceravolo, Roberto ^a   Logi, Chiara ^a   Berti, Caterina ^a   Rossi, Giuseppe ^c   Bianchi, Maria Cristina ^d,e   Tosetti, Michela ^e   Murri, Luigi ^a   Bonuccelli, Ubaldo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Hospital of Viareggio   (Italy)

^c CNR   (Italy)

^d Dept of Clin Microbiol Lab   (Italy)

^e DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

Author keywords

Dopamine agonists; Parkinson's disease; Pergolide; Spectroscopy

Indexed keywords

CHOLINE; CREATINE; DOMPERIDONE; N ACETYLASPARTIC ACID; PERGOLIDE;

ADULT; AGED; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MECHANISM; FEMALE; FOLLOW UP; HUMAN; MALE; MOTOR CORTEX; MOTOR PERFORMANCE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SOMNOLENCE; STRIATE CORTEX; TREATMENT OUTCOME;

ADULT; AGED; ASPARTIC ACID; CHOLINE; CREATININE; DOPAMINE AGONISTS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MOTOR CORTEX; PARKINSON DISEASE; PERGOLIDE; PROTONS; TREATMENT OUTCOME;

EID: 38049000872     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21576     Document Type: Article

References (34)

1. Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol 2001;8:573-577.
2. O'Neill J, Schuff N, Marks WJ, et al. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 2002;17:917-927.
3. Hoang TQ, Bluml S, Dubowitz DJ, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's disease. Neurology 1998;50:1033-1040.
4. Tedeschi G, Litvan I, Bonavita S, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997;120:1541-1552.
5. Bowen BC, Block RE, Sanchez-Ramos J, et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol 1995;16:161-168.
6. Duyckaerts C, Verny M, Hauw JJ. Recent neuropathology of parkinsonian syndromes. Rev Neurol 2003;159:3S11-3S18.
7. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318:121-134.
8. Wakabayashi K, Mori F, Oyama Y, et al. Lewy bodies in Betz cells of the motor cortex in a patient with Parkinson's disease. Acta Neuropathol (Berl) 2003;105:189-192.
9. Samuel M, Ceballos-Baumann AO, Blin J, et al. Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements: a PET study. Brain 1997;120:963-976.
10. Haslinger B, Erhard P, Kampfe N, et al. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 2001;124:558-570.
11. Sabatini U, Boulanouar K, Fabre N, et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain 2000;123:394-403.
12. Rothwell JC. Pathophysiology of the motor cortex in patients with Parkison's disease. Adv Neurol 1999;80:27-29.
13. Mascalchi M, Tosetti M, Plasmati R. et al. Proton magnetic resonance spectroscopy in an Italian family with spinocerebellar ataxia type 1. Ann Neurol 1998;43:244-252.
14. Bianchi MC, Tosetti M, Battini R. et al. Proton MR spectroscopy of mitochondrial diseases: analysis of brain metabolic abnormalities and their possible diagnostic relevance. AJNR Am J Neuroradiol 2003;24:1958-1966.
15. Schirmer T, Auer DP. On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain. NMR Biomed 2000;13:28-36.
16. Holshouser BA, Komu M, Moller HE, et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study. Magn Reson Med 1995;33:589-594.
17. Ray-Chaudhuri K, Lemmens GM, Williams SCR, et al. Proton magnetic resonance spectroscopy of the striatum in Parkinson's disease patients with motor response fluctuations. Parkinsonism Relat Disord 1996;2:63-67.
18. Ellis CM, Lemmens G, Williams SC, et al. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology 1997;49:438-444.
19. Clarke CE, Lowry M. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol 2000;7:661-665.
20. Hu MT, Taylor-Robinson SD, Ray-Chaudhuri KR, et al. Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. J Neurol Neurosurg Psychiatry 1999;67:20-26.
21. Camicioli R, Hanstock C, Bouchard T, et al. Pre-supplementary motor area changes are found in Parkinson's disease using magnetic resonance spectroscopy. Neurology 2006;66 (Suppl. 2): A112-A113 (abstract).
22. Miller BL. A review of chemical issues in 1H NMR spectroscopy: N-acetylaspartate, creatine and choline. NMR Biomed 1991;4:47-52.
23. Ebisu T, Rooney WD, Graham SH, et al. N-acetylasprtate as in vivo marker of neuronal viability in kainate-induced status epilepticus: 1H magnetic resonance spectroscopic imaging. J Cereb Blood Flow Metab 1994;14:373-382.
24. Dautry C, Condé F, Brouillet E, et al. Serial 1H NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol Dis 1999;6:259-268.
25. Demougeot C, Garnier P, Mossiat C, et al. N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. J Neurochem 2001;77:408-415.
26. Block W, Traber F, Flacke S, et al. In-vivo proton MR-spectroscopy of the human brain: assessment of N-acetylaspartate (NAA) reduction as a marker for neurodegeneration. Amino Acids 2002; 23:317-323.
27. De Graaf AA, Deutz NEP, Bosman DK, et al. The use of in vivo proton NMR to study the effects of hyperammonemia in the rat cerebral cortex. NMR Biomed 1991;4:31-37.
28. Mir P, Matsunaga K, Gilio F, et al. Dopaminergic drugs restore facilitatory premotor-motor interactions in Parkinson disease. Neurology 2005;64:1906-1912.
29. Ziemann U, Bruns D, Paulus W. Enhancement of human motor cortex Inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation. Neurosci Lett 1996;208:187-190.
30. Clarke CE, Lowry M, Horsman A. Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov Disord 1997;13:297-301.
31. Baik HM, Choe BY, Lee HK, et al. Metabolic alterations in Parkinson's disease after thalamotomy, as revealed by (1)H MR spectroscopy. Korean J Radiol 2002;3:180-188.
32. Baik HM, Choe BY, Son BC, et al. Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy. Eur J Radiol 2003;47:179-187.
33. Vion-Dury J, Nicoli F, Salvan A, et al. Reversal of brain metabolic alternons with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet 1994;345:60-61.
34. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995; 34:721-727.